by Service [Pharmaceutical Manufacturing Services (API, FDF), Drug Development Services, Biologics Development], End User [Big & Generic Pharmaceutical Companies] – Global Forecast to 2027," published by Meticulous Research
®, the pharmaceutical contract development and manufacturing market is expected to grow at a CAGR of 6.5% from 2020 to 2027 to reach $134.23 billion by 2027.
A pharma contract manufacturing company offers various services to drug companies, including drug development, drug manufacturing and commercial production, development of drug formulation, and biological manufacturing. A pharmaceutical CDMO serves pharmaceutical companies on a contract basis to provide all the above comprehensive services. This allows major pharmaceutical companies to outsource those aspects of the business, which can help with scalability or allow the major company to focus on drug discovery and drug marketing.